{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T04:38:43Z","timestamp":1794026323974,"version":"4.8.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic kidney disease is a global health challenge, especially in resource-limited regions. Understanding its burden and key risk factors is crucial for effective interventions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data from the Global Burden of Disease Study (1990\u20132021) covering 204 countries were analyzed to assess trends in prevalence, mortality, and disability-adjusted life years for chronic kidney disease, alongside geographic, age, sex, and risk factor patterns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>In 2021, an estimated 674 million individuals were affected globally. Although the global age-standardized prevalence rate declined slightly by 0.8% since 1990, substantial disparities persisted. High-income North America\u2019s prevalence remained stable yet showed high mortality (20.6 per 100,000) and increased DALYs (508.8 per 100,000). In contrast, East Asia\u2019s prevalence fell by 11.7%, accompanied by notable reductions in mortality (11.1 per 100,000) and DALYs (322.4 per 100,000). Regions with low socio-demographic indices, including parts of sub-Saharan Africa and South Asia, bore the greatest burdens, with persistently high prevalence (exceeding 9000 per 100,000) and rising DALYs. Some countries, such as Guatemala, experienced rapid prevalence increases, while others, like Italy, achieved substantial reductions. Similarly, mortality trends varied: Ukraine saw steep increases, while Poland showed marked improvements. DALY burdens also diverged, with El Salvador experiencing large increases, and Kuwait recording significant declines. Prevalence peaked at ages 65\u201369 in males and 70\u201374 in females, with female rates surpassing male rates from the early thirties onward. High fasting plasma glucose contributed 36% of DALYs globally, heavily affecting the Caribbean and high-income North America. High systolic blood pressure and high body mass index were particularly influential in Central Europe and high-income North America, respectively. Low fruit intake strongly affected the Middle East and East Asia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interpretation<\/jats:title>\n                    <jats:p>These findings underscore persistent global inequalities in CKD outcomes, necessitating region-specific strategies and strengthened healthcare capacity to mitigate the burden.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2025.1563246","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:10:13Z","timestamp":1751501413000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Global burden of chronic kidney disease and its attributable risk factors (1990-2021): an analysis based on the global burden of disease study"],"prefix":"10.3389","volume":"16","author":[{"given":"Min-Jia","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Yong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Qiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Rong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41581-024-00820-6","article-title":"Chronic kidney disease and the global public health agenda: an international consensus","volume":"3","author":"Francis","year":"2024","journal-title":"Nat Rev Nephrol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","author":"Bikbov","year":"2020","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e000453","DOI":"10.1136\/bmjgh-2017-000453","article-title":"Do attributes of persons with chronic kidney disease differ in low-income and middle-income countries compared with high-income countries? Evidence from population-based data in six countries","volume":"2","author":"Anand","year":"2017","journal-title":"BMJ Global Health"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-019-0248-y","article-title":"Targeting the progression of chronic kidney disease","volume":"16","author":"Ruiz-Ortega","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcad.2018.07.005","article-title":"Obesity and kidney disease","volume":"61","author":"Lakkis","year":"2018","journal-title":"Prog Cardiovasc Dis"},{"key":"B6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nrneph.2015.173","article-title":"Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease","volume":"12","author":"Thomas","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15747","article-title":"Cardiovascular and non-renal complications of chronic kidney disease: managing risk","author":"Rossing","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2013.12.012","article-title":"Cost-effectiveness of primary screening for CKD: a systematic review","volume":"63","author":"Komenda","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2020.07.037","article-title":"Adherence to chronic kidney disease screening guidelines among patients with type 2 diabetes in a US administrative claims database","volume":"96","author":"Folkerts","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32977-0","article-title":"The global burden of chronic kidney disease","volume":"395","author":"Cockwell","year":"2020","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2017.88","article-title":"Chronic kidney disease","volume":"3","author":"Romagnani","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-021-00454-y","article-title":"Pro-resolving lipid mediators: regulators of inflammation, metabolism and kidney function","volume":"17","author":"Brennan","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2024.04.021","article-title":"Environmental pollution to kidney disease: an updated review of current knowledge and future directions","volume":"106","author":"Lao","year":"2024","journal-title":"Kidney Int"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.envres.2018.10.005","article-title":"Global burden of late-stage chronic kidney disease resulting from dietary exposure to cadmium, 2015","volume":"169","author":"Zang","year":"2019","journal-title":"Environ Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00476-8","article-title":"Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950\u20132021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021","volume":"403","author":"Schumacher","year":"2024","journal-title":"Lancet"},{"key":"B16","unstructured":"Global health data exchange\n          \n          \n          \n          2024"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012026.pub2","article-title":"Interventions for improving health literacy in people with chronic kidney disease","volume":"12","author":"Campbell","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"B18","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nrneph.2015.4","article-title":"Nephrology in the developing world: Chronic kidney disease in disadvantaged populations","volume":"11","author":"Garcia-Garcia","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","article-title":"Epidemiology of chronic kidney disease: an update 2022","volume":"12","author":"Kovesdy","year":"2022","journal-title":"Kidney Int Suppl"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60178-5","article-title":"Chronic kidney disease","volume":"379","author":"Levey","year":"2012","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2017.188","article-title":"Kidneys and women\u2019s health: key challenges and considerations","volume":"14","author":"Ashuntantang","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2014.31","article-title":"Novel targets of antifibrotic and anti-inflammatory treatment in CKD","volume":"10","author":"Decl\u00e8ves","year":"2014","journal-title":"Nat Rev Nephrol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2013.152","article-title":"Stromal cells in tissue homeostasis: balancing regeneration and fibrosis","volume":"9","author":"Rabelink","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.kisu.2017.07.003","article-title":"Reducing major risk factors for chronic kidney disease","volume":"7","author":"Luyckx","year":"2017","journal-title":"Kidney Int Suppl"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32064-5","article-title":"Chronic kidney disease","volume":"389","author":"Webster","year":"2017","journal-title":"Lancet"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2016.191","article-title":"Kidney disease and obesity: epidemiology, mechanisms and treatment","volume":"13","author":"C\u00e2mara","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15683","article-title":"What every clinician needs to know about chronic kidney disease: Detection, classification and epidemiology","author":"Selby","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"B28","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3390\/ijms22010043","article-title":"New potential biomarkers for chronic kidney disease management\u2014A review of the literature","volume":"22","author":"Lousa","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.kisu.2017.07.005","article-title":"Strategies to improve monitoring disease progression, assessing cardiovascular risk, and defining prognostic biomarkers in chronic kidney disease","volume":"7","author":"Pena","year":"2017","journal-title":"Kidney Int Suppl"},{"key":"B30","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.kisu.2017.07.002","article-title":"Action plan for determining and monitoring the prevalence of chronic kidney disease","volume":"7","author":"Coresh","year":"2017","journal-title":"Kidney Int Suppl"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/jech-2014-204621","article-title":"Are estimates of socioeconomic inequalities in chronic disease artefactually narrowed by self-reported measures of prevalence in low-income and middle-income countries? Findings from the WHO-SAGE survey","volume":"69","author":"Sukumar Vellakkal","year":"2015","journal-title":"J Epidemiol Community Health"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1563246\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:10:17Z","timestamp":1751501417000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1563246\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":31,"alternative-id":["10.3389\/fendo.2025.1563246"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1563246","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,3]]},"article-number":"1563246"}}